Back to top

Analyst Blog


DaVita, the dialysis unit of kidney care service provider, DaVita HealthCare Partners Inc. (DVA - Analyst Report) entered into a strategic alliance with Cureatr with the aim to improve nationwide communication and care coordination among care teams at dialysis centers. Cureatr offers mobile care coordination solution for healthcare providers.

DaVita provides an extensive range of healthcare services to patients throughout the United States and abroad. However, it encounters serious care coordination challenges. Thus, in order to optimize care coordination and generate reports on key quality measures for improvement, it requires adequate technological support. Cureatr’s enterprise messaging and workflow navigation solutions will ensure better clinical information sharing for DaVita.

DaVita has already implemented Cureatr solutions in its operations in Atlanta and is upbeat on the prospects as it has received a favorable response. Additionally, the company aims to expand its scale of operations and eventually utilize Cureatr solutions in other locations.

This partnership will allow DaVita to offer the iPhone and web apps of Cureatr to its facility administrators, care managers, nurses and affiliated nephrologists. To improve communication within the dialysis care teams of DaVita, the provision will include Health Insurance Portability and Accountability Act (HIPAA)-secure group messaging system with read receipts, secure photo sharing technology, and seamless integration with the existing scheduling and directory systems. This facilitates doctors, nurses and other care-team members to provide high quality care to their patients.

We believe that this partnership will auger well for DaVita as Cureatr’s proficiency will aid the company to overcome communication barriers and deliver more efficient patient care as well as induce growth.

Among its recent ventures, last week, DaVita and Myriad RBM entered into a strategic liaison to perform a protein biomarker discovery research. Myriad RBM is a wholly owned subsidiary of a leading molecular diagnostic company, Myriad Genetics Inc. (MYGN - Analyst Report). The objective is to develop and introduce diagnostic tests into the market for the better treatment of dialysis patients.

DaVita currently carries a Zacks Rank #3 (Hold). Among others in the industry, China Cord Blood Corporation (CO - Snapshot Report) carries a Zacks Rank #2 (Buy) while Adus HomeCare Corporation (ADUS - Snapshot Report) carries a favorable Zacks Rank #1 (Strong Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%